NIH Grants Exclusive License for HPV 16 Cancer Cell Therapy Invention
Published Date: 9/15/2026
Notice
Summary
The National Cancer Institute plans to give MedGene Therapeutics an exclusive license to develop and sell special engineered cell treatments for cancers caused by HPV 16 E6. This means MedGene will have the sole right to use these inventions, potentially speeding up new cancer therapies. If you want to comment or apply for a license, you must do so by September 30, 2026.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 0 costs, 1 mixed.
Exclusive NIH License for HPV‑16 T‑cell Therapy
If you are a patient with an HPV‑16 E6–positive cervical, head and neck (including oropharyngeal), or anogenital cancer and you express HLA‑A*02, the National Cancer Institute is contemplating granting MedGene Therapeutics an exclusive, royalty-bearing patent license to develop and commercialize ex vivo engineered T‑cell therapies (autologous or allogeneic) that use T‑cell receptors reactive to the HPV‑16 E6 oncoprotein. The contemplated exclusive territory may include the United States, Japan, and the Republic of Korea, and written comments or license applications must be received by the NCI Technology Transfer Center on or before September 30, 2026 (notice published September 15, 2026).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20771, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the NIH is holding several closed virtual meetings in early November 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, affecting researchers seeking funding. No direct money changes are announced, but these reviews decide who gets research grants.
2026-20705, Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Antibody Specifically Binding to Severe Fever With Thrombocytopenia Syndrome Virus Antigen and Use Thereof
The National Institute of Allergy and Infectious Diseases plans to give Korea National Institute of Health an exclusive license to develop and sell a special antibody that targets a dangerous virus causing severe fever and low platelets. This deal helps speed up turning the invention into real-world treatments. Comments or license requests must be sent by October 26, 2026.
2026-20424, National Cancer Institute; Notice of Meeting
The President's Cancer Panel is holding a free virtual meeting on October 15, 2026, to talk about how GLP-1 medications can help lower cancer risks linked to obesity. Anyone interested can join online or send in comments beforehand. This meeting is a great chance for patients, doctors, and researchers to learn about new ways to fight cancer and improve health.
2026-20365, Center For Scientific Review; Notice of Closed Meetings
The NIH's Center for Scientific Review is holding several closed virtual meetings on October 29-30, 2026, to review and evaluate grant applications. These meetings protect private info and trade secrets while deciding which research projects get funding. Scientists applying for grants in areas like biochemistry, software engineering, and mental health will be affected, with no direct money changes announced but important decisions coming soon.
2026-20151, Notice of NIH Tribal Consultations and Listening Session
The NIH is inviting Tribal leaders and members to join two important meetings and a listening session during the National Congress of American Indians Annual Convention in October 2026. They’ll talk about new health research projects, renewing support for Tribal health centers, and shaping a new Tribal Data Sovereignty Policy. Tribes can also send their thoughts by November 20, 2026, helping shape future health programs and policies.
2026-19719, Center for Scientific Review; Amended Notice of Meeting
The NIH’s Center for Scientific Review is shortening a key meeting from two days to just one day on October 13, 2026, keeping the same 9 a.m. to 6 p.m. hours. This change affects members of the Surgical Sciences and Bioengineering review group and means less time in the room but no public access. No money changes or delays are expected—just a quicker, tighter meeting!
Previous / Next Documents
Previous: 2026-18876, Notice of OFAC Sanctions Action
On September 10, 2026, the U.S. Treasury’s Office of Foreign Assets Control (OFAC) blocked the property and financial interests of certain people and groups by adding them to a special sanctions list. This means U.S. citizens and companies can’t do business with them anymore. These actions help protect U.S. interests and enforce important rules about who can access money and property under U.S. control.
Next: 2026-18878, In the Matter of The Nasdaq Stock Market LLC; Order Granting Petitions for Review and Scheduling Filing of Statements Regarding an Order Approving a Proposed Rule Change, as Modified by Amendment No. 1, To Adopt a New Continued Listing Requirement
The Nasdaq Stock Market is updating its rules to make sure companies keep meeting certain standards to stay listed. This change affects all companies listed on Nasdaq and aims to keep the market strong and trustworthy. The new rule was reviewed and approved after public comments, with deadlines set for companies to comply and for further statements to be filed.